PR Newswire (Wed, 9:00AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,137 people get AVNR articles and Market Currents by email alert.
Get email alerts on AVNR »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
PR Newswire (May 8, 2013)
-
PR Newswire (Apr 26, 2013)
-
-
-
PR Newswire (Mar 11, 2013)
-
PR Newswire (Mar 1, 2013)
-
PR Newswire (Feb 14, 2013)
-
PR Newswire (Feb 7, 2013)
-
-
PR Newswire (Jan 30, 2013)
-
-
-
PR Newswire (Dec 12, 2012)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
6 Liquid Small-Cap Healthcare Stocks Projected For Strong GrowthZetaKap • Thu, Aug 30, 2012 -
-
-
-
-
-
-
-
-
-
-
-
Avanir's CEO Discusses Q4 2011 Results - Earnings Call TranscriptMon, Dec 12, 2011 • 1 Comment
-
PR Newswire (Wed, 9:00AM)
-
PR Newswire (May 8, 2013)
-
PR Newswire (Apr 26, 2013)
-
PR Newswire (Mar 11, 2013)
-
PR Newswire (Mar 1, 2013)
-
PR Newswire (Feb 14, 2013)
-
PR Newswire (Feb 7, 2013)
-
PR Newswire (Jan 30, 2013)
-
PR Newswire (Dec 12, 2012)
-
PR Newswire (Nov 21, 2012)
-
PR Newswire (Sep 20, 2012)
-
PR Newswire (Sep 14, 2012)
-
PR Newswire (Sep 5, 2012)
AVNR vs. ETF Alternatives
Company Description
AVANIR is a pharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. Our lead product candidate, Zenviatm (dextromethorphan hydrobromide/quinidine sulfate), has successfully completed three Phase... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, May 8, 4:11 PM Avanir Pharmaceuticals (AVNR): FQ2 EPS of -$0.12 misses by $0.02. Revenue of $17.4M in-line. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, May 8, 12:10 AM Notable earnings after Wednesday’s close: AHT, ALJ, ATLS, ATVI, AVNR, CF, CLNE, CLR, CTL, CTRP, CUZ, CXW, DEPO, DK, ERII, ETE, ETP, GMCR, GRPN, GSS, HALO, HEK, HNSN, JOE, LPSN, MBLX, MDR, MED, MIDD, MM, MNST, MNTX, MWE, NWSA, OSUR, PPO, PVA, QTM, RAX, RGP, RIG, RST, SGMO, SPRD, SSRI, STEC, SXL, SZYM, TCAP, TSLA, WR, XTEX Comment! [Earnings]
- Tuesday, May 7, 5:35 PM Notable earnings after Wednesday’s close: AHT, ALJ, ATLS, ATVI, AVNR, CF, CLNE, CLR, CTL, CTRP, CUZ, CXW, DEPO, DK, ERII, ETE, ETP, GMCR, GRPN, GSS, HALO, HEK, HNSN, JOE, LPSN, MBLX, MDR, MED, MIDD, MM, MNST, MNTX, MWE, NWSA, OSUR, PPO, PVA, QTM, RAX, RGP, RIG, RST, SGMO, SPRD, SSRI, STEC, SXL, SZYM, TCAP, TSLA, WR, XTEX Comment! [Earnings]
-
Friday, April 26, 9:11 AM
Premarket gainers: LOGM +19%. AVNR +16%. SYNA +17%. QLIK +12%. CRIS +9%. DHI +7%. THRX +7%. MUX +7%. JCP +7%. CSTR +6%.
Losers: PKI -14%. SIMO -11%. BIDU -9%. KEG -8%. SDT -5%. Comment! [On the Move] - Friday, April 26, 8:20 AM Avanir Pharmaceuticals (AVNR) jumps 14% premarket after the Committee for Medicinal Products for Human Use recommends approval of NUEDEXTA for the treatment of pseudobulbar affect. The company says the positive opinion is an important milestone on the road to getting "the only evidence-based treatment for PBA approved in the European Union." Comment! [Healthcare, On the Move]
- Thursday, February 7, 4:48 PM More on Avanir Pharmaceuticals (AVNR): FQ1 loss narrows, but misses Street estimates despite solid sales growth. Total revenue soared by over 130% Y/Y, driven largely by a 20% increase in Nuedexta revenue plus royalty revenue from Abreva. Shares +4% AH. Comment! [Healthcare, Earnings, On the Move]
- Thursday, February 7, 4:18 PM Avanir Pharmaceuticals (AVNR): FQ1 EPS loss of $0.09 misses by $0.01. Revenue of $16.5M (+130% Y/Y) in line. (PR). Comment! [Healthcare, Earnings, Breaking News]
- Thursday, February 7, 8:49 AM A Phase I study demonstrates that Avanir Pharmaceuticals' (AVNR) AVP-786 compound has a comparable pharmacokinetic, safety and tolerability profile to the company's AVP-923, which is being trialed for use in patients with Alzheimer's disease, Multiple Sclerosis, Parkinson's and autism. As a results, Avanir believes "AVP-786 would be an ideal candidate to test in one or more of our ongoing clinical programs." (PR) Comment! [Healthcare]
- Thursday, February 7, 12:10 AM Notable earnings after Thursday’s close: AGNC, ALNY, ASYS, ATHN, ATVI, AVNR, CSTR, DCT, FLT, G, HAS, LNKD, MCHP, NCR, NFG, NUAN, OPEN, PRI, RGC, RSG, RVBD, SNCR, SPWR, TSRA, UBNT, WWWW, XL Comment! [Earnings]
- Wednesday, February 6, 5:35 PM Notable earnings after Thursday’s close: AGNC, ALNY, ASYS, ATHN, ATVI, AVNR, CSTR, DCT, FLT, G, HAS, LNKD, MCHP, NCR, NFG, NUAN, OPEN, PRI,RGC, RSG, RVBD, SNCR, SPWR, TSRA, UBNT, WWWW, XL Comment! [Earnings]
-
Friday, December 14, 2012, 5:39 PM
After-hours top gainers, as of 5:15 p.m.: ETH +10%. TVL +7%. AVG +5%. ARQL +5%. EZPW +4%.
After-hours top losers: CADX -6%. AVNR -5%. ITG -5%. BEBE -5%. ISIS -4%. 1 Comment [On the Move] - Wednesday, December 12, 2012, 4:04 PM Avanir Pharmaceuticals (AVNR): FQ4 EPS of -$0.09 misses by $0.01. Revenue of $13.5M beats by $0.6M. (PR) Comment! [Earnings, Healthcare]
- Wednesday, December 12, 2012, 12:10 AM Notable earnings after Wednesday’s close: AVNR Comment! [Earnings]
- Tuesday, December 11, 2012, 5:35 PM Notable earnings after Wednesday’s close: AVNR Comment! [Earnings]
- Wednesday, August 8, 2012, 4:13 PM Avanir Pharmaceuticals (AVNR): FQ3 EPS of -$0.11 in-line. Revenue of $10.5M misses by $1.1M. (PR) Comment! [Earnings, Healthcare]
- Wednesday, August 8, 2012, 12:10 AM Notable earnings after Wednesday’s close: ATPG, AUY, AVNR, CJES, CLR, CPE, CPNO, CTL, EGLE, EXXI, FTK, GMXR, GSS, GXP, HNSN, HOGS, KGC, MBI, MDRX, MM, MNST, NQ, NWSA, ONTY, PANL, SATC, SCLN, SGEN, SPWR, TEG, ZGNX Comment! [Earnings]
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.